

# DOMESTIC ANIMAL ENDOCRINOLOGY

Domestic Animal Endocrinology 24 (2003) 123-135

www.elsevier.com/locate/jnlabr/dae

# Detection and quantification of mRNA expression of $\alpha$ - and $\beta$ -adrenergic receptor subtypes in the mammary gland of dairy cows

T. Inderwies <sup>a</sup>, M.W. Pfaffl <sup>a</sup>, H.H.D. Meyer <sup>a</sup>, J.W. Blum <sup>b</sup>, R.M. Bruckmaier <sup>a,\*</sup>

<sup>a</sup> Institute of Physiology, Technical University Munich, D-85354 Freising-Weihenstephan, Germany b Faculty of Veterinary Medicine, Institute of Animal Genetics, Nutrition and Housing, University of Berne, CH-3012 Berne, Switzerland

Received 22 May 2002; accepted 16 August 2002

#### **Abstract**

Adrenergic receptors are pharmacologically classified into the receptor types  $\alpha_1$ ,  $\alpha_2$ ,  $\beta_1$ ,  $\beta_2$ , and  $\beta_3$ . Structural differences and varying affinities in radioligand binding studies lead to a further classification of  $\alpha_1$ - and  $\alpha_2$ -receptors into subtypes which are termed  $\alpha_{1A}$  (formerly  $\alpha_{1C}$ ),  $\alpha_{1B}$ , and  $\alpha_{1D}$  (formerly  $\alpha_{1AD}$ ), and  $\alpha_{2AD}$ ,  $\alpha_{2B}$ , and  $\alpha_{2C}$ , respectively. mRNA expression of all but one  $\alpha$ -adrenergic receptor subtypes and of all  $\beta$ -adrenergic receptor types was measured quantitatively in total RNA extracted from mammary tissue of 10 lactating dairy cows by real-time reverse transcription (RT) polymerase chain reaction (PCR). mRNA expression of  $\alpha_1$ -adrenergic receptors was highest for the  $\alpha_{1A}$ -subtype followed by  $\alpha_{1B}$ , whereas the  $\alpha_{1D}$ -subtype could not be detected. The highest mRNA expression of  $\alpha_2$ -adrenergic receptors was found for the  $\alpha_{2AD}$ -subtype, followed by  $\alpha_{2B}$  and  $\alpha_{2C}$ . Within the  $\beta$ -adrenergic receptors, the  $\beta_2$ -receptor type was most highly expressed, followed by  $\beta_1$  and  $\beta_3$ .

In conclusion, eight of nine adrenergic receptors classified to date were detected and relatively quantified in the mammary gland of dairy cows.

© 2002 Elsevier Science Inc. All rights reserved.

Keywords: mRNA expression; Real-time RT-PCR; Adrenergic receptor types and subtypes; Bovine mammary gland

<sup>\*</sup> Corresponding author. Tel.: +49-8161-71-4429; fax: +49-8161-71-4204. *E-mail address:* bruckmaier@wzw.tum.de (R.M. Bruckmaier).

#### 1. Introduction

The various physiological effects of the adrenergic system in different tissues are mediated by binding of catecholamines to alpha ( $\alpha$ )- and beta ( $\beta$ )-adrenergic receptors. Adrenergic receptors belong to the family of G-protein-coupled receptors which are located in the cell membrane. The primary structure of these proteins is remarkably similar; most characteristic are seven stretches of hydrophobic transmembrane spanning domains which are connected by alternating intracellular and extracellular loops, with the amino terminus located on the extracellular side and the carboxy terminus on the intracellular side. The binding sites for adrenergic ligands are contained in a binding crevice formed by transmembrane spanning domains [1]. So far,  $\alpha$ - and  $\beta$ -adrenergic receptors have been pharmacologically classified into the receptor types  $\alpha_1$  and  $\alpha_2$ , and  $\beta_1$ ,  $\beta_2$  and  $\beta_3$ , respectively. Between these receptor types there are functional differences and often antagonistic effects, e.g. vasoconstriction mediated by  $\alpha_1$ - and  $\alpha_2$ -receptors and vasodilation mediated by  $\beta_2$ -receptors [2].

Structural differences and varying affinities in radioligand binding studies within the  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor type show heterogeneity and lead to a further classification into receptor subtypes [3]. Several molecular cloning studies suggest that there are three distinct subtypes of  $\alpha_1$ -adrenergic receptors, originally classified as  $\alpha_{1AD}$ ,  $\alpha_{1B}$  and  $\alpha_{1C}$  [4,5] and four distinct subtypes of  $\alpha_2$ -adrenergic receptors,  $\alpha_{2A}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$  and  $\alpha_{2D}$  [6,7]. Recently,  $\alpha_{2A}$ - and  $\alpha_{2D}$ -adrenergic receptors were combined to one receptor subtype  $\alpha_{2AD}$  [8,9] as they seem to be variants of the same adrenergic receptor between species, the  $\alpha_{2A}$  in human and porcine and the  $\alpha_{2D}$  in rat, murine and bovine, differing in one amino acid only [10].

According to a recent classification of adrenergic receptors in human pharmacological research  $\alpha_1$ -adrenergic receptors were subdivided into  $\alpha_{1A}$  (formerly  $\alpha_{1C}$ ),  $\alpha_{1B}$  and  $\alpha_{1D}$  (formerly  $\alpha_{1AD}$ ), whereas the  $\alpha_2$ -subclassification remained as described above [2]. In this study, we kept to the new classification into three  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor subtypes each, which are designated A, B, and D ( $\alpha_1$ ), and AD, B and C ( $\alpha_2$ ), respectively. The former nomenclature of the  $\alpha_1$ -adrenergic receptor subtypes is additionally shown in brackets.

So far, expression of  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor subtypes has been studied mainly in rat but also in human, rabbit and other species by Northern blot analysis. Diversity of tissue distribution of  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor subtypes indicate that different species may express different receptor subtypes in different tissues [3].

Especially vascular adrenergic receptor subtypes play an important role in human pharmacological research [11]. In veterinary research, however, functional purposes of  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor subtypes have not been discussed yet whereas pharmacological functions of the adrenergic receptor types  $\alpha_1$  and  $\alpha_2$ , and  $\beta_1$ ,  $\beta_2$  and  $\beta_3$ , respectively, are well known. In the bovine mammary gland, stimulation of  $\beta$ -adrenergic receptors facilitates milk removal [12,13] whereas  $\alpha$ -adrenergic receptor stimulation reduces total milk yield and peak flow rate [14,15]. The presence of  $\alpha_1$ -,  $\alpha_2$ - and  $\beta$ -adrenergic receptor binding sites in the bovine mammary gland has been demonstrated previously [16–19]. On the level of mRNA expression, only two adrenergic receptor (sub)types, the  $\alpha_{1A(C)}$ - and  $\beta_2$ -adrenergic receptor, were detected in the bovine mammary gland [20].

We tested the hypothesis that those six  $\alpha$ -adrenergic receptor subtypes ( $\alpha_{1A(C)}$ ,  $\alpha_{1B}$ ,  $\alpha_{1D(AD)}$ ,  $\alpha_{2AD}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$ ) and three  $\beta$ -adrenergic receptor types ( $\beta_1$ ,  $\beta_2$ ,  $\beta_3$ ) are present in

the mammary gland of dairy cows. Therefore, a highly sensitive and quantitative method, a real-time reverse transcription (RT) polymerase chain reaction (PCR), was developed to detect and quantify the mRNA expression of these receptors.

#### 2. Materials and methods

# 2.1. Total RNA preparation and cDNA synthesis

Mammary tissue samples of the udder of 10 lactating cows were taken immediately after slaughter, snap frozen in liquid nitrogen, and stored at  $-80\,^{\circ}$ C. For RNA preparation, 200 mg of mammary tissue was homogenized with an Ultra-Turrax homogenizer (T 25, Janke & Kunkel, Staufen, Germany) using 2 ml TriPure Isolation Reagent (Roche Diagnostics, Mannheim, Germany) followed by 5 min of incubation at room temperature (rt). After addition of 0.4 ml chloroform, 10-min incubation at rt, and centrifugation for 15 min at  $13,500 \times g$  and  $4\,^{\circ}$ C, the RNA being in the upper aqueous phase was carefully pipetted and precipitated by adding 0.5 ml iso-2-propanol and centrifuged for  $10\,\text{min}$  at  $13,500 \times g$  at  $4\,^{\circ}$ C. RNA pellets were washed with 75% ethanol and again centrifuged at  $8000 \times g$  for 8 min at  $4\,^{\circ}$ C. The supernatant was decanted completely, and after drying for  $10\,\text{min}$  at  $37\,^{\circ}$ C, the remaining pellet was diluted in  $30\,\mu$ l RNase-free water.

In order to quantify the extracted total RNA, optical density of the RNA stock solution was determined at 260 nm. Additionally, optical density of the  $OD_{260\,nm}/OD_{280\,nm}$  (nucleic acid/protein) absorption ratio was measured which lay in an optimum range between 1.8 and 2.0. The stock solution was diluted into a work solution of  $100\,ng/\mu l$  by RNase-free water and again optically determined at  $260\,nm$ .

Synthesis of first strand complementary DNA (cDNA) was performed with 200 units reverse transcriptase (MMLV-RT, Promega, Madison, WI, USA) and 100 pmol random hexamer primers (MBI Fermentas, St. Leon-Rot, Germany). Final concentration of reversely transcribed total RNA was  $25 \text{ ng/}\mu l$ .

#### 2.2. Oligonucleotide primers

Nine different primer pairs (sense and antisense primer) were designed using published bovine or human nucleic acid sequences [8,21–28]. To demonstrate the amplification of only the cDNA but not the genomic DNA (gDNA) the sense and antisense primers of every target gene were placed in two different exons of the gene. So the length of the PCR products of cDNA and gDNA differed.

Oligonucleotide primers for each subtype were designed by multiple sequence alignments of published nucleotide sequences of different species (HUSAR program, DKFZ, Heidelberg, Germany). In regions of high homology primers were designed from nucleotide sequences of about 20 bp long. Another multiple sequence alignment between sequences of the subtypes within one receptor type (e.g.  $\alpha_{2AD}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$ ) showed very low homology and verified that regions of designed oligonucleotide primers were subtype specific.

Primer information, product length, and the EMBL ac. numbers are listed in Table 1.

Table 1 Sequence of PCR primers, position of the primers (f = forward; r = reverse) in the coding sequence (CDS), PCR product length, and EMBL ac. no. (species in brackets) of the used published nucleic acid sequences

Primer	Sequence $(5' \rightarrow 3')$	CDS	Length	EMBL ac. no.
$\alpha_{1A(C)} f$ $\alpha_{1A(C)} r$	GTGAACATTTCCAAGGCCAT GGTCGATGGAGATGATGCAG	61–80 351–370	310	J05426 (bovine)
$\begin{array}{l} \alpha_{1B} \ f \\ \alpha_{1B} \ r \end{array}$	ACTTCACTGGCCCCAACCAG TACTGCAGAGAGTAGCGCAC	71–90 439–458	388	L31773 (human)
$\begin{array}{l} \alpha_{1D(AD)} \; f \\ \alpha_{1D(AD)} \; r \end{array}$	ACCTGCAGACCGTCACCAACTA GGTGCAGAGGCTGAGGA	392–413 566–582	191	D29952 (human)
$\begin{array}{l} \alpha_{2AD} \ f \\ \alpha_{2AD} \ r \end{array}$	TCATCTCGGCCGTCATCTCCTT CGCACATAGACCAGGATCATGAT	476–497 631–653	178	U79030 (bovine)
$\begin{array}{l} \alpha_{2B} \ f \\ \alpha_{2B} \ r \end{array}$	TTGCTGGGCTACTGGTACTTC TACCAGGCCTCTTGGTTGAGCT	220–239 494–515	296	Y15944 (bovine)
$\begin{array}{l} \alpha_{2C} \ f \\ \alpha_{2C} \ r \end{array}$	TGCGCGCCCGCAGAACCTCTTCCT ATGCAGGAGGACAGGATGTACCA	245–269 625–647	403	NM_000683 (human)
$eta_1 f \ eta_1 r$	TCGCCCTTCCGCTACCAGA ACTCGGGGTCGTTGTAGCA	566–584 707–725	160	AF188187 (bovine)
$eta_2 f \ eta_2 r$	TCATGTCGCTTATTGTCCTGG CACCAGAAGTTGCCAAAAGTCC	116–136 296–317	202	Z86037 (bovine)
β <sub>3</sub> f β <sub>3</sub> r	ACCGTGGGAGGCAACCTG TGGCCGGTCAGCGCCAA	151–168 289–305	155	X85961 (bovine)
UbC f UbC r	AGATCCAGGATAAGGAAGGCAT GCTCCACCTCCAGGGTGAT	86–107 721–739	654	Z18245 (bovine)
GAPDH f GAPDH r	GTCTTCACTACCATGGAGAAGG TCATGGATGACCTTGGCCAG	265–286 442–461	197	U85042 (bovine)

# 2.3. Quantification by real-time PCR

Polymerase chain reaction was performed in the LightCycler (Roche Diagnostics) with 25 ng reversely transcribed total RNA (25 ng/ $\mu$ l). Further reaction components for the LightCycler reactions were 1.0  $\mu$ l LightCycler FastStart Mastermix (Roche) (containing Taq DNA Polymerase, reaction buffer, 10 mM MgCl<sub>2</sub>, dNTP mix, and SYBR Green I dye), 4 mM MgCl<sub>2</sub>, 4 pmol forward primer, 4 pmol reverse primer, and sterile water up to a final volume of 10  $\mu$ l.

Prior to amplification an initial denaturation step (10 min at 95 °C) ensured complete denaturation of the cDNA. All PCR reactions were performed with a total of 40 amplification cycles. Product-specific PCR cycle conditions for all receptor (sub)types and the housekeeping genes are summarized in Table 2. After the last amplification cycle, PCR products were specified in a melting curve analysis as each product has its specific melting temperature depending on the GC-content (Table 2). In this way it could be demonstrated that there were no primer dimers or unspecific amplification products.

To verify the specificity of each PCR quantification method the PCR amplicons were sequenced (MWG BIOTECH, Ebersberg, Germany). For each product three PCR runs

 $87.5 \pm 0.0$ 

 $88.4 \pm 0.1$ 

Adrenergic receptor	Denaturation		Primer annealing		Elongation		Melting temperature
(sub)type and hkg	(°C)	(s)	(°C)	(s)	(°C)	(s)	(°C) mean $\pm$ S.E.M.; n = 10
$\alpha_{1A(C)}$	95	600	60	10	72	20	$90.3 \pm 0.0$
$\alpha_{1B}$	95	600	60	10	72	20	$91.0 \pm 0.1$
$\alpha_{1D(AD)}$	95	600	60	10	72	10	$86.9 \pm 0.1$
$\alpha_{2AD}$	95	600	65	10	72	20	$89.1 \pm 0.1$
$\alpha_{2B}$	95	600	65	10	72	20	$91.3 \pm 0.1$
$\alpha_{2C}$	95	600	65	10	72	20	$93.4 \pm 0.1$
$\beta_1$	95	600	60	10	72	10	$92.8 \pm 0.0$
$\beta_2$	95	600	60	10	72	10	$88.8 \pm 0.1$
$\beta_3$	95	600	60	10	72	10	$91.9 \pm 0.1$

Table 2
Product-specific LightCycler-PCR conditions of adrenergic receptor (sub)types and housekeeping genes (hkg) ubiquitin (UbC) and glyceraldehyde-phosphate-dehydrogenase (GAPDH)

Total number of cycles: 40.

UbC

**GAPDH** 

were performed to gain sufficient amounts of PCR amplicons. Comparison between the sequenced PCR product and the corresponding published coding sequence resulted in a nucleotide sequence identity of at least 95–100% (HUSAR program, DKFZ, Heidelberg, Germany).

10

10

72

72

25

20

Ubiquitin (UbC) and glyceraldehyde-phosphate-dehydrogenase (GAPDH) were chosen to confirm constant housekeeping gene (hkg) expression levels in the investigated cDNA samples [29,30]. Given the possibility that these genes, too, are regulated to a certain extent, the mean value of UbC and GAPDH for each sample was chosen to gain an optimum of constant expression level.

#### 2.4. Mathematical and statistical evaluations

95

95

600

600

62

58

mRNA expression was evaluated by amplification curve analysis of the LightCycler real-time RT-PCR. After incorporation into double stranded DNA (dsDNA), SYBR Green I (DNA binding dye) shows fluorescence emission and increases according to target amplification with cycle number. The exponential phase of the PCR becomes detectable when the fluorescence signal from accumulated PCR product is greater than the background fluorescence. To eliminate uniformative fluorescence background points, a fixed fluorescence threshold line is set to the exponential portion of the amplification curve as low as possible (in this case at a fluorescence level of 3) without including any background points. The intersection of the threshold line and the amplification curve represents the crossing point value [31].

Crossing points (CP) for each receptor (sub)type were determined at a constant fluorescence threshold line for all receptor (sub)types (fit points method; [31]). CP results are shown as raw data of the PCR amplification program of the LightCycler for each receptor (sub)type and for the hkg UbC and GAPDH. The hkg mean value of each sample was used

for a normalization of the amount of every target gene which results in the  $\Delta$ CP value. The  $\Delta\Delta$ CP value represents the difference between the  $\Delta$ CP of the target gene and of the lowest expressed adrenergic receptor subtype within each receptor type (= $\alpha_{1B}$ ,  $\alpha_{2C}$ ,  $\beta_3$ ) or within all nine receptor (sub)types (= $\beta_3$ ), respectively. Relative expression levels within each receptor type are given by the arithmetic formula  $2^{-\Delta\Delta}$ CP [32]. The logarithm dualis (log 2) is based on an optimum efficiency (*E*) of PCR which is E=2 where the PCR product is replicated every cycle.

Data are presented as means  $\pm$  S.E.M. For statistical evaluations the SAS program package [33] was used. Effects of the animal and the adrenergic receptor type were tested for significance (P < 0.05) by ANOVA using the General Linear Model (GLM) procedure. Differences between receptor subtype gene expression within each receptor type ( $\alpha_1$ ,  $\alpha_2$ , and  $\beta$ ) were localized with the least significance difference test (LSD).

#### 3. Results

# 3.1. Confirmation of primer and PCR-product specificity

Specificity of the desired products in bovine mammary gland total RNA was documented with melting curve analysis and additionally with high resolution gel electrophoresis. Derived mean melting temperatures of PCR products were product-specific and are listed in Table 2.

#### 3.2. Bovine $\alpha_{1B}$ -, $\alpha_{1D(AD)}$ -, and $\alpha_{2C}$ -sequences

Three of the nine distinct adrenergic receptor (sub)types were previously not described as bovine nucleotide sequences:  $\alpha_{1B}$ ,  $\alpha_{1D(AD)}$ , and  $\alpha_{2C}$ .

The  $\alpha_{1D(AD)}$ -adrenergic receptor subtype was not detectable in the bovine mammary gland on the level of mRNA expression. There was a definite product peak in the real-time

Table 3 Crossing points (CP), shown as raw data (mean  $\pm$  S.E.M.; n=10) of the PCR amplification program of the LightCycler for each adrenergic receptor (sub)type and for the housekeeping genes (hkg) UbC and GAPDH

Adrenergic receptor (sub)type and hkg	СР	Significance within the receptor types $\alpha_1$ , $\alpha_2$ , and $\beta$ ( $P < 0.05$ )		
α <sub>1A(C)</sub> α <sub>1B</sub>	$28.19 \pm 0.45$ $30.74 \pm 0.51$	a b		
$egin{array}{l} lpha_{2AD} \ lpha_{2B} \ lpha_{2C} \end{array}$	$27.11 \pm 0.23$ $31.34 \pm 0.17$ $32.39 \pm 0.12$	a b c		
$\beta_1$ $\beta_2$ $\beta_3$	$29.94 \pm 0.25$ $28.51 \pm 0.30$ $32.81 \pm 0.42$	b a c		
UbC GAPDH	$19.80 \pm 0.29$ $22.96 \pm 0.21$	- -		

(a–c): means without common letters are significantly different (P < 0.05).

PCR but the PCR product length was lower than required. Complete sequencing of this nucleotide fragment was not possible. A 388 bp fragment for the  $\alpha_{1B}$ -adrenergic receptor subtype, which is 94.3, 91.0, and 89.6%, respectively, homologue with corresponding regions of human, rat and mouse nucleotide sequences was identified (Fig. 1), and a 403 bp fragment

bovine					CCCCAACCAG	
human	51	~~~~~~~	~~~~~~~			
rat	51	~~~~~~~	~~~~~~~			
mouse	51	~~~~~~	~~~~~~			
bovine		ACTCCACACT	GCCTCAGCTG	GACATCACCA	GGGCCATCTC	CGTGGGCCTG
human			C			T
rat			C	G		T
mouse			C	G		TTGT
bovine				CTTTGCCATC		
human						
rat						
mouse						-CT-G
bovine				GTCACCTGCG		
human				-G		
rat				-G		
mouse		-CG		-G	A	
bovine		TCGTCAACCT	GGCCATTGCC	GACCTGCTGC	TAAGCTTCAC	CGTTCTGCCC
human		-T	G	<b>T</b>	-G	C
rat			T	T	-GT	AA
mouse		-T	T	T	-G	A-AC
bovine		TTCTCTGCTG	CCCTGGAGGT	GCTTGGCTAC	TGGGTGCTGT	TCTGGATCTT
human				C		
rat		A	AA			-GA-TT
mouse		A	A	C	G	GGC-C
bovine				TGGATGTCCT		
human						
rat				-A		
mouse			AG-	-T	TG	C-
bovine		TAAGCCTGTG	CGCCATCTCC	ATCGACCGCT	ACATTGGGGT	GCGCTACTCT
human				T		
rat				T		
mouse		-GA	T	T		T
bovine		CTGCAGTA~~	460			
human		~~				
rat		~~~	460			
mouse		~~	460			

Fig. 1. Partial nucleotide sequence of bovine  $\alpha_{1B}$ -adrenergic receptor subtype (new EMBL ac. no. AJ488280) and its alignment to human (EMBL ac. no. L31773), rat (EMBL ac. no. M60655), and mouse (EMBL ac. no. Y12738)  $\alpha_{1B}$ -adrenergic receptor. Primer localisations are framed.

for the  $\alpha_{2C}$ -adrenergic receptor subtype, which is 94.5, 93.1, and 92.3%, respectively, homologue with corresponding regions of human, rat and mouse nucleotide sequences (Fig. 2). The new nucleotide fragments have been submitted to the EMBL Nucleotide Sequence Databases and assigned the accession numbers AJ488280 ( $\alpha_{1B}$ ) and AJ488281 ( $\alpha_{2C}$ ).

bovine human 201 rat 201 mouse 201					TGCGCG	
bovine human rat mouse	-GA		GTGTCGCTGGT	GC A		
bovine human rat mouse	G		CTCGCTGGCC T T T-T			
bovine human rat mouse	 T		GCGGCGTGTA  -TT -TTA	C AG	TGG- G	
bovine human rat mouse	-T	G	CACCTGTGCGTT-			
bovine human rat mouse	G G	-G -GAG	CGAGTACAAC  A A		-AA	
bovine human rat mouse	T	C-	CCGTGTGGCT	T		
bovine human rat mouse		GG CTT	TACCGCCGGC			
bovine human rat mouse	C		GACCTGGTAC			650

Fig. 2. Partial nucleotide sequence of bovine  $\alpha_{2C}$ -adrenergic receptor subtype (new EMBL ac. no. AJ488281) and its alignment to human (EMBL ac. no. NM\_000683), rat (EMBL ac. no. M58316), and mouse (EMBL ac. no. NM\_007418)  $\alpha_{2C}$ -adrenergic receptor. Primer localisations are framed.

Table 4 Relative mRNA expression of  $\alpha_1$ -,  $\alpha_2$ - and  $\beta_2$ -adrenergic receptor (sub)types and hkg (n = 10)

Adrenergic receptor (sub)type	$\Delta$ CP (target – mean hkg)	$\Delta\Delta \text{CP} \left(\Delta \text{CP}_{\text{target}} - \Delta \text{CP}_{\text{lowest expressed (sub)type}}\right)$	<i>x</i> -fold mRNA expression $(2^{-\Delta \Delta CP})$	$\Delta\Delta CP$ ( $\Delta CP_{target}$ – $\Delta CP_{lowest}$ expressed adr. rec.)	<i>x</i> -fold mRNA expression $(2^{-\Delta\Delta CP})$
$\alpha_{1A(C)}$	$+6.81 \pm 0.37^{a}$	$-2.55 \pm 0.37$	5.86 (4.53–7.57)	$-4.62 \pm 0.37$	24.59 (19.03–31.78)
$\alpha_{1B}$	$+9.36 \pm 0.44^{b}$	$0.00 \pm 0.44$	1.00 (0.74–1.36)	$-2.07 \pm 0.44$	4.20 (3.10–5.70)
$\alpha_{2AD}$	$+5.74 \pm 0.18^{a}$	$-5.27 \pm 0.18$	38.59 (34.06–43.71)	$-5.69 \pm 0.18$	51.63 (45.57–58.49)
$\alpha_{2B}$	$+9.97 \pm 0.27^{b}$	$-1.04 \pm 0.27$	2.06 (1.71–2.48)	$-1.46 \pm 0.27$	2.75 (2.28–3.32)
$\alpha_{2C}$	$+11.01 \pm 0.21^{c}$	$0.00 \pm 0.21$	1.00 (0.86–1.16)	$-0.42 \pm 0.21$	1.34 (1.16–1.55)
$\beta_1$	$+8.56 \pm 0.26^{b}$	$-2.87 \pm 0.26$	7.31 (6.11–8.75)	$-2.87 \pm 0.26$	7.31 (6.11–8.75)
$\beta_2$	$+7.13 \pm 0.17^{a}$	$-4.30 \pm 0.17$	19.70 (17.51–22.16)	$-4.30 \pm 0.17$	19.70 (17.51–22.16)
$\beta_3$	$+11.43 \pm 0.42^{c}$	$0.00 \pm 0.42$	1.00 (0.75–1.34)	$0.00 \pm 0.42$	1.00 (0.75–1.34)

(a–c): corresponding means (within one receptor type) without common superscript letters are significantly different (P < 0.05). Column 2:  $\Delta$ CP (CP difference) presents each receptor (sub)type CP value normalized to an internal reference (mean hkg CP value). Columns 3 and 5:  $\Delta$  $\Delta$ CP values are evaluated as the normalized target genes ( $\Delta$ CP values) are relative to a calibrator, which is the lowest expressed receptor (sub)type within each of the three receptor types  $\alpha_1$ ,  $\alpha_2$  and  $\beta$  (column 3), or within all adrenergic receptor (sub)types ( $=\beta_3$ ) (column 5). Columns 4 and 6: Relative mRNA expression levels within each of the three receptor types  $\alpha_1$ ,  $\alpha_2$  and  $\beta$  (column 4) and within all nine adrenergic receptor (sub)types (column 6) are given by the arithmetic formula  $2^{-\Delta}$ CP assuming that the efficiency (E) of the PCR is E = 2 where the PCR product is replicated every cycle ( $\Delta$  $\Delta$ CP – S.E.M. and  $\Delta$  $\Delta$ CP + S.E.M. are shown in brackets giving a range for the mRNA expression).

Sequence alignments (to verify a subtype specific product amplification) between the amplified product sequence and sequences already known showed high homology within one (sub)type ( $\alpha_{1A(C)}$ : 88–100%,  $\alpha_{1B}$ : 88–95%;  $\alpha_{2AD}$ : 82–100%,  $\alpha_{2B}$ : 86–100%,  $\alpha_{2C}$ : 84–95%;  $\beta_1$ : 87–100%,  $\beta_2$ : 87–100%,  $\beta_3$ : 86–99%). Sequence alignments between the amplified product sequence and sequences of other (sub)types resulted in low homology (between  $\alpha_1$ -adrenergic receptor subtypes: 67–73%; between  $\alpha_2$ -adrenergic receptor subtypes: 68–72%; between  $\beta$ -adrenergic receptor types: 55–71%).

# 3.3. Distribution of mRNA expression

mRNA of almost all adrenergic receptor types and subtypes classified to date could be detected. mRNA expression levels of the various receptor (sub)types are shown as uncorrected CP values in Tables 3 and 4 within each of the three receptor types  $\alpha_1$ ,  $\alpha_2$  and  $\beta$  (column 4), and within all receptor types and subtypes (column 6).

The  $\alpha_{2AD}$ -receptor subtype shows highest expression levels not only among the  $\alpha_{2}$ -receptors, followed by  $\alpha_{2B}$  and  $\alpha_{2C}$ , but also in comparison with all adrenergic receptor (sub)types. Within the  $\alpha_{1}$ -receptor type mRNA of the  $\alpha_{1A(C)}$ -subtype is most frequent, followed by  $\alpha_{1B}$ , and within the  $\beta$ -receptors the  $\beta_{2}$ -receptor type is most highly expressed, followed by  $\beta_{1}$  and  $\beta_{3}$ .

On the level of mRNA expression the receptor (sub)types are distributed as follows:  $\alpha_{1A(C)} > \alpha_{1B}$ ,  $\alpha_{2AD} > \alpha_{2B} > \alpha_{2C}$ , and  $\beta_2 > \beta_1 > \beta_3$ . Expression levels of the adrenergic receptor subtypes show noticeable differences within each of the receptor types  $\alpha_1$ ,  $\alpha_2$  and  $\beta$  (Tables 3 and 4).

#### 4. Discussion

In this study, mRNA expression of almost all established adrenergic receptor types and subtypes were detected in the mammary gland of dairy cows. Adrenergic receptors are classified into nine adrenergic receptor types and subtypes. Within the  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor type there are three subtypes each:  $\alpha_{1A(C)}$ ,  $\alpha_{1B}$ ,  $\alpha_{1D(AD)}$ , and  $\alpha_{2AD}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$ , and within the  $\beta$ -adrenergic receptor there are three receptor types:  $\beta_1$ ,  $\beta_2$ , and  $\beta_3$  [9,11].

For six of those nine receptor (sub)types, bovine nucleotide sequences had been published; for the remaining three factors ( $\alpha_{1B}$ ,  $\alpha_{1D(AD)}$ , and  $\alpha_{2C}$ ) human sequences were used for the primer design. The new bovine nucleotide fragments ( $\alpha_{1B}$  and  $\alpha_{2C}$ ) could be amplified by PCR and sequenced.

For the  $\alpha_{1D(AD)}$ -adrenergic receptor subtype the primer design seemed to be successful looking at the real-time PCR results showing a specific product peak which was reproducible in many different mammary gland and also liver cDNAs. The length of this PCR product, however, was approximately 80 bp shorter than expected and sequencing of this fragment was only partially successful. Thus, it can be concluded that the amplified PCR product of the  $\alpha_{1D(AD)}$ -adrenergic receptor subtype is not the one required and, even more, that the  $\alpha_{1D(AD)}$ -adrenergic receptor subtype perhaps does not occur in the bovine mammary gland.

Different mRNA expression levels could be shown by variation of crossing points (CP) of all receptor (sub)types in the LightCycler RT-PCR. The CP indicates the cycle number

at which the fluorescence signal of the amplified target reaches a fixed threshold line. The higher the initial amount of genomic DNA, the sooner accumulated PCR product is detected in the PCR process, and the lower is the CP value.

The amount of target gene was normalized to an internal reference, which was the mean of the housekeeping genes UbC and GAPDH. Housekeeping genes are expected to be unaffected by experimental treatments, i.e. show constant expression levels and thus serve as control genes. In this study, UbC as well as GAPDH showed similar but not identical mRNA expression patterns in the investigated samples (n=10). Working with the mean values of both housekeeping genes perhaps mirrors best a constant expression level that can be used for a normalization of the target genes.

Values of the normalized target genes ( $=\Delta CP$  values) were given relative to a calibrator gene which is an arbitrary constant [34]. In this study, the lowest expressed receptor subtype within each of the three receptor types ( $=\alpha_{1B}$ ,  $\alpha_{2C}$ ,  $\beta_{3}$ ) and on the other hand the lowest expressed receptor subtype of all adrenergic receptor (sub)types ( $=\beta_{3}$ ) were chosen as calibrators. The resulting values are termed as  $\Delta\Delta CP$  as the calibrator value itself is a normalized target gene, i.e. a  $\Delta CP$  value.

mRNA expression was evaluated by the formula  $2^{-\Delta\Delta CP}$  assuming that the efficiency (E) of the PCR is E=2, which means that the PCR amplicons were duplicated every cycle.

On the level of mRNA expression, the  $\beta_2$ -receptor was the most abundant  $\beta$ -receptor type in the bovine mammary gland. Expression levels of  $\beta_1$ - and  $\beta_3$ -receptor mRNA were not surprisingly lower than of the  $\beta_2$ -receptor;  $\beta_1$ -adrenergic receptors were described to mediate mainly cardiovascular responses to endogenous catecholamines [11]. The  $\beta_3$ -receptor type is the most capable adrenergic receptor for inducing lipolysis and thus is present mainly in fat tissues [35]. In earlier investigations receptor binding sites [19] as well as receptor mRNA [20] of the  $\beta_2$ -receptor were found in the mammary gland of cows. In receptor binding studies varying affinities of  $\beta$ -specific antagonists indicated a predominant  $\beta_2$ -receptor population and a small number of  $\beta_1$ -adrenergic receptors in teat muscles [16].

Distribution of  $\alpha_2$ -adrenergic receptor subtypes-mRNA in the bovine mammary gland corresponded with earlier studies that described the  $\alpha_{2AD}$ -adrenergic receptor subtype as the most abundant one located post- as well as presynaptically in different tissues and species [2]. Measuring mRNA-levels by Northern blot—also in different tissues and species—indicated a higher distribution of the  $\alpha_{1A(C)}$ - and  $\alpha_{1B}$ -receptor subtype than of the  $\alpha_{1D(AD)}$ -receptor subtype [2] which was also matching with our results obtained by RT-PCR.

Mean receptor density found in teat tissue by radioligand binding studies was highest for  $\alpha_2$ -receptors, and slightly lower for  $\alpha_1$ -receptors [17,18]. Those earlier findings are difficult to compare with the distribution of  $\alpha_1$ - and  $\alpha_2$ -adrenergic receptor subtypes on the level of mRNA expression because the available ligands were not subtype selective.

In conclusion, eight of nine known adrenergic receptor types and subtypes were detected in the mammary gland of dairy cows on the level of mRNA expression despite their low abundance. Expression levels of adrenergic receptor subtypes vary considerably.

# Acknowledgements

This study was funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.

#### References

- Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90–113.
- [2] Civantos Calzada B, de Artinano AA. Alpha-adrenergic receptor subtypes. Pharmacol Res 2001;44:195–208.
- [3] Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG. Molecular biology of α-adrenergic receptors: implications for receptor classification and for structure–function relationships. Biochim Biophys Acta 1991;1095:127–39.
- [4] Garcia-Sainz JA, Romero-Avila MT, Alcantara Hernandez R, Macias-Silva M, Olivares-Reyes A, Gonzales-Espinosa C. Species heterogeneity of hepatic alpha 1-adrenergic receptors:  $\alpha_{1A}$ -,  $\alpha_{1B}$  and  $\alpha_{1C}$ -subtypes. Biochem Biophys Res Commun 1992;186:760–7.
- [5] Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Localization of mRNA for three distinct  $\alpha_1$ -adrenergic receptor subtypes in human tissues: implications for human  $\alpha$ -adrenergic physiology. Mol Pharmacol 1994;45:171–5.
- [6] Blaxall HS, Heck DA, Bylund DB. Molecular determinants of the  $\alpha_{2D}$ -adrenergic receptor subtype. Life Sci 1993;53:255–9.
- [7] Kurose H, Lefkowitz RJ. Differential desensitization and phosphorylation of three cloned and transfected α<sub>2</sub>-adrenergic receptor subtypes. J Biol Chem 1994;269:10093–9.
- [8] Venkataraman V, Duda T, Sharma RK. The bovine α<sub>2D</sub>-adrenergic receptor gene: structure, expression in retina, and pharmacological characterization of the encoded receptor. Mol Cell Biochem 1997;177:113–23.
- [9] Venkataraman V, Duda T, Sharma RK. The  $\alpha_{2D/A}$ -adrenergic receptor-linked membrane guanylate cyclase: a new signal transduction system in the pineal gland. FEBS Lett 1998;427:69–73.
- [10] Hieble JP, Bondinell WE, Ruffolo Jr RR. Alpha- and beta-adrenergic receptors: from the gene to the clinic. 1. Molecular biology and adrenergic receptor subclassification. J Med Chem 1995;38:3415–44.
- [11] Guimaraes S, Moura D. Vascular adrenergic receptors: an update. Pharmacol Rev 2001;53:319-56.
- [12] Bernabé J, Peeters G. Studies on the motility of smooth muscles of the teats in lactating cows. J Dairy Res 1980;47:259–75.
- [13] Blum JW, Schams D, Bruckmaier R. Catecholamines, oxytocin and milk removal in dairy cows. J Dairy Res 1989;56:167–77.
- [14] Bruckmaier R, Mayer H, Schams D. Effects of  $\alpha$  and  $\beta$ -adrenergic agonists on intramammary pressure and milk flow in dairy cows. J Dairy Res 1991;58:411–9.
- [15] Bruckmaier RM, Wellnitz O, Blum JW. Inhibition of milk ejection in cows by oxytocin receptor blockade, α-adrenergic receptor stimulation and in unfamiliar surroundings. J Dairy Res 1997;64:315–25.
- [16] Roets E, Peeters G, Leysen JE. Identification of β-adrenergic receptors in bovine teat muscles by <sup>3</sup>H-dihydroalprenolol binding. Archives Internationales de Pharmacodynamie et de Therapie 1984;270:203– 14
- [17] Roets E, Peeters G. Identification and characterization of  $^3$ H-Prazosin binding to  $\alpha_1$ -adrenergic receptors in bovine teat muscles. Archives Internationales de Pharmacodynamie et de Therapie 1985;275:189–98.
- [18] Roets E, Peeters G. A comparison of the binding characteristics of the  $\alpha_2$ -adrenergic receptor antagonists  ${}^{3}$ H-Yohimbine and  ${}^{3}$ H-Rauwolscine in bovine teat muscles. Archives Internationales de Pharmacodynamie et de Therapie 1986;279:212–22.
- [19] Hammon HM, Bruckmaier RM, Honegger UE, Blum JW. Distribution and density of  $\alpha$  and  $\beta$ -adrenergic receptor binding sites in the bovine mammary gland. J Dairy Res 1994;61:47–57.
- [20] Wellnitz O, Zurbriggen A, Friis RR, Blum JW, Bruckmaier RM. α<sub>1C</sub>- and β<sub>2</sub>-adrenergic receptor mRNA distribution in the bovine mammary gland detected by competitive RT-PCR. J Dairy Res 2001;68:699–704.
- [21] Schwinn DA, Lomasney JW, Lorenz W, Szklut PJ, Fremeau Jr RT, Yang-Feng TL, et al. Molecular cloning and expression of the cDNA for a novel α<sub>1</sub>-adrenergic receptor subtype. J Biol Chem 1990;265:8183–9.
- [22] Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM. Genomic organization and expression of the human α<sub>1B</sub>-adrenergic receptor. J Biol Chem 1992;267:21936–45.
- [23] Esbenshade TA, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman KP, et al. Cloning of the human  $\alpha_{1d}$ -adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Mol Pharmacol 1995;47:977–85.
- [24] Madsen O. EMBL/GeneBank, accession Y15944, 1999.

- [25] Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning and expression of a human kidney cDNA for an α<sub>2</sub>-adrenergic receptor subtype. Proc Natl Acad Sci USA 1988;85:6301–5.
- [26] Ha SH, Baik MG, Choi YF. EMBL/GeneBank, accession AF188187, 1999.
- [27] Einspanier R, Gabler C, Kloas W. EMBL/GeneBank, accession Z86037, 1997.
- [28] Pietri-Rouxel F, Lenzen G, Kapoor A, Drumare MF, Archimbault P, Strosberg AD, et al. Molecular cloning and pharmacological characterization of the bovine β<sub>3</sub>-adrenergic receptor. Eur J Biochem 1995;230:350–8.
- [29] Wempe F, Scheit KH. EMBL/GeneBank, accession Z18245, 1993.
- [30] Mertens B, Muriuki C. EMBL/GeneBank, accession U85042, 1997.
- [31] Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, editors. Rapid cycle real-time PCR, methods and applications. Heidelberg: Springer; 2001, p. 21–34.
- [32] User Bulletin No. 2. Relative quantification of gene expression. Applied Biosystems, Foster City, CA, 2001.
- [33] SAS. SAS/STAT user's guide, release 8.01. SAS Institute, Cary, NC, 1999.
- [34] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C}_T$  method. Methods 2001;25:402–8.
- [35] Louis SN, Jackman GP, Nero TL, Iakovidis D, Louis WJ. Role of beta-adrenergic receptor subtypes in lipolysis. Cardiovasc Drugs Ther 2000;14:565–77.